A busy few weeks across life science and biotech. Here’s what’s worth knowing from late March 2026, with context for what it means for researchers and scientists working in the field.
In Vivo CAR-T Cell Therapy: A Major Technical Advance in Nature
The most significant life science paper of the week came out of UCSF and UC Berkeley on March 18. Researchers from the Eyquem and Doudna laboratories published a study in Nature demonstrating the first successful site-specific integration of a CAR gene into human T cells without removing the cells from the body.
Current CAR-T therapies require a complex manufacturing process: blood is taken from the patient, T cells are isolated and engineered in a specialized facility over three to five weeks, and then reinfused. That process is expensive (often hundreds of thousands of dollars per patient), inaccessible in much of the world, and sometimes impossible for patients who are too ill for leukapheresis.
The new approach uses a two-vector delivery system to bring the CAR gene directly to T cells in a living organism and inserts it at the TRAC locus — the same site targeted in high-end ex vivo manufacturing — for regulated expression. In humanized mouse models, in vivo-generated CAR-T cells achieved sustained tumor control in leukemia, multiple myeloma, and a solid tumor model.
Three of the study authors co-founded Azalea Therapeutics to advance this toward clinical trials. This is still preclinical, but the mechanism is solid and the implications for patient access are substantial if it translates. We covered this paper in more depth in this week’s research post.
Retatrutide Phase 3: The Next Weight Loss Drug Shows Strong Results
Eli Lilly reported Phase 3 results from its TRIUMPH-4 trial for retatrutide this week. Participants taking the 12mg dose lost an average of 28.7% of body weight (approximately 71.2 pounds) at 68 weeks. Those on the 9mg dose lost 26.4% on average.
Retatrutide is a triple agonist that targets GLP-1, GIP, and glucagon receptors simultaneously — a more aggressive mechanism than semaglutide (which targets GLP-1 only) or tirzepatide (GLP-1 and GIP). The results are consistent with what the mechanism would predict: greater weight loss but also more side effects. The discontinuation rate due to adverse events was 18.2% at the high dose (12mg) and 12.2% at the lower dose (9mg), compared to about 4% in the placebo arm. Gastrointestinal side effects (nausea, diarrhea, vomiting) drove most of the discontinuations.
For context: semaglutide achieves roughly 15% weight loss on average, tirzepatide around 20-22%. Retatrutide’s 28.7% would represent a meaningful step up in efficacy, though the tolerability gap will be a real clinical consideration. Seven additional Phase 3 readouts for retatrutide are expected in 2026.
What this means for researchers: The GLP-1/incretin biology field continues to generate compelling clinical results at a pace that’s unusual in drug development. If you work in metabolic disease, obesity, or cardiometabolic biology, this is the most active clinical space in the field right now.
NIH Foreign Grant Crackdown Is Disrupting International Collaborations
A STAT News report from March 27 describes the widening impact of NIH restrictions on foreign subawards. NIH’s current policy significantly limits the ability of US-based investigators to route grant funding to international collaborators, including longstanding scientific partnerships at major research institutions.
The practical impact is already being felt: some collaborative grants are being restructured to remove foreign subawards entirely, and international co-investigators on existing grants are being decoupled from US funding. Scientists from institutions in countries subject to enhanced scrutiny (including China) face particular challenges, and some established research collaborations are being wound down.
This follows a broader pattern of US science policy becoming more restrictive about international research ties — a trend that has been building since 2019. The scientific community has consistently raised concerns about the chilling effect on global collaborations, particularly in fields like genomics and infectious disease where international data sharing and joint studies have been enormously productive.
What this means: If you’re working on grants with international co-investigators, check your program officer guidance and your institution’s research compliance team before your next renewal cycle. The rules have tightened materially in the past 18 months.
China’s Biotech Rise Is Reshaping Drug Development
The same STAT News report notes a broader trend: China’s biotech industry is maturing rapidly, with Chinese companies increasingly licensing drugs to Western multinationals rather than simply receiving technology transfers. Several major licensing deals in 2025-2026 have involved Chinese companies as originators of drug candidates acquired by US and European pharma.
This represents a structural shift. For years, the flow of drug development knowledge and assets ran predominantly from West to East. That’s no longer uniformly true. The oncology space in particular has seen multiple Chinese-developed compounds enter late-stage development in Western markets.
What this means for researchers: If you’re evaluating the competitive landscape for a target area or considering biotech/pharma career opportunities, Chinese companies are worth tracking as originators, not just as licensees or manufacturers.
Gossamer Bio Cuts 48% After Phase 3 Miss
Gossamer Bio cut approximately 48% of its workforce this week after its Phase 3 trial of seralutinib in pulmonary arterial hypertension (PAH) missed its primary endpoint. The company is now evaluating strategic alternatives — a phrase that typically signals a sale or wind-down process.
Seralutinib is an inhaled PDGFR/FGFR/CSF1R inhibitor that had shown promise in early trials. The Phase 3 miss is a reminder that PAH, despite being a target-rich indication with approved drugs, remains difficult to advance new mechanisms in — partly because the approved therapies set a high bar for improvement in a patient population that’s not large.
This is the latest in a period of biotech volatility that, per Fierce Biotech’s 2026 layoff tracker, has continued even as deal-making has recovered.
Brief Notes
Eli Lilly and NVIDIA are building a drug discovery supercomputer. The partnership announced this month will use NVIDIA’s infrastructure for molecular simulation at a scale not previously practical. This falls in line with the broader industry trend of AI and ML as core R&D infrastructure rather than optional add-ons.
Kodiak Sciences’ vision loss treatment succeeded in a second Phase 3 trial. KSI-301 — an anti-VEGF biopolymer conjugate — showed efficacy in wet AMD in a confirmatory trial. This is meaningful for a company that had an earlier Phase 3 setback in this program.
That’s the week. Subscribe to the Digest for these roundups delivered every week, plus tool reviews and career resources for life scientists.